By Josh White
Date: Wednesday 08 Jan 2025
(Sharecast News) - Cambridge Cognition announced the use of its 'CANTAB' cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for 'Cobenfy', a newly FDA-approved treatment for schizophrenia.
By Iain Gilbert
Date: Tuesday 10 Dec 2024
(Sharecast News) - Brain health software group Cambridge Cognition said on Tuesay that full-year revenues were expected to be no less than £10.0m, while adjusted underlying earnings was seen at close to breakeven.
By Josh White
Date: Friday 18 Oct 2024
(Sharecast News) - Cambridge Cognition, a provider of digital solutions for assessing brain health, announced the formal resignation of Dr Matthew Stork as a director of the company and its subsidiaries on Friday.
Currency | UK Pounds |
Share Price | 42.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 57.98 |
52 Week Low | 27.50 |
Volume | 32,016 |
Shares Issued | 41.94m |
Market Cap | £17.61m |
RiskGrade | 282 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
15:29 | 25,000 @ 42.53p |
13:21 | 108 @ 42.53p |
12:13 | 23 @ 43.00p |
11:36 | 2,000 @ 42.53p |
09:57 | 1,065 @ 41.75p |
You are here: research